Since the DGUOK‐AS1/miR‐145‐5p/SIX1 axis is dysregulated in cancer, correlates with prognosis, and controls DNL, and SIX1 KO attenuates NAFLD progression, this axis is expected to be a promising therapeutic target for curing liver cancer and NAFLD. The gene discussed is SIX1; the disease is metabolic dysfunction-associated steatotic liver disease.